Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura

von Willebrand factor propeptide to antigen ratio in acquired thrombotic thrombocytopenic purpura

(2012) F. STUFANO et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura

(2011) Spero R. Cataland et al.   AMERICAN JOURNAL OF HEMATOLOGY

Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs

(2011) H. Ulrichts et al.   BLOOD

How I treat patients with thrombotic thrombocytopenic purpura: 2010

(2010) J. N. George   BLOOD

Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus)

(2010) H. B. Feys et al.   BLOOD

Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura

(2010) Luca A. Lotta et al.   BRITISH JOURNAL OF HAEMATOLOGY

Regulation of von Willebrand factor-platelet interactions

(2010) Julie Pegon et al.   THROMBOSIS AND HAEMOSTASIS

Basal secretion of von Willebrand factor from human endothelial cells

(2008) J. P. Giblin et al.   BLOOD

Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura

(2008) J. E. Sadler   BLOOD

Current management of thrombotic thrombocytopenic purpura

(2008) Johanna A Kremer Hovinga et al.   CURRENT OPINION IN HEMATOLOGY

Long-term deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpura

(2008) Qurana F. Lewis et al.   TRANSFUSION